![Dirk Brockstedt](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Dirk Brockstedt
Consultant / Advisor chez
ShangPharma Innovation, Inc.
Profil
Dirk G.
Brockstedt is currently Executive-in-Residence at ShangPharma Innovation, Inc. Former positions include Chief Scientific Officer at Rapt Therapeutics, Inc. from 2018 to 2026, Executive Vice President-Research & Development at Aduro BioTech, Inc. from 2016 to 2017, Director-Research at Anza Therapeutics, Inc. from 2007 to 2009, Immunology Director at Cerus Corp.
from 2002 to 2007, and Senior Research Scientist at Aventis, Inc. Education includes graduate and doctorate degrees from the University of Kiel.
Postes actifs de Dirk Brockstedt
| Sociétés | Poste | Début |
|---|---|---|
ShangPharma Innovation, Inc.
 ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation invests in companies located in the United States. The firm targets companies operating in the fields of healthcare sector. It provides financing for seed to early stage capital requirements. | Consultant / Advisor | - |
Anciens postes connus de Dirk Brockstedt
| Sociétés | Poste | Fin |
|---|---|---|
| RAPT THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 03/03/2026 |
| CHINOOK THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/12/2017 |
Anza Therapeutics, Inc.
 Anza Therapeutics, Inc. Medical SpecialtiesHealth Technology Develops therapeutic vaccines for cancer and infectious diseases | Directeur Technique/Scientifique/R&D | 01/01/2009 |
| CERUS CORPORATION | Corporate Officer/Principal | 01/01/2007 |
Aventis, Inc.
 Aventis, Inc. MiscellaneousMiscellaneous Functions as an investment holding company | Corporate Officer/Principal | - |
Formation de Dirk Brockstedt
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
59
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Cerus Corp.
 Cerus Corp. Medical SpecialtiesHealth Technology Develops and commercializes the INTERCEPT Blood System for platelets and plasma | Health Technology |
Aventis, Inc.
Aventis, Inc. MiscellaneousMiscellaneous Functions as an investment holding company | Miscellaneous |
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company, which focuses on the development of technology platforms for cancer | Health Technology |
University of Kiel
 University of Kiel Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Anza Therapeutics, Inc.
Anza Therapeutics, Inc. Medical SpecialtiesHealth Technology Develops therapeutic vaccines for cancer and infectious diseases | Health Technology |
Rapt Therapeutics, Inc.
 Rapt Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes oral small molecule therapies for patients | Health Technology |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation invests in companies located in the United States. The firm targets companies operating in the fields of healthcare sector. It provides financing for seed to early stage capital requirements. | Finance |
